0001213900-21-032952.txt : 20210617 0001213900-21-032952.hdr.sgml : 20210617 20210617160008 ACCESSION NUMBER: 0001213900-21-032952 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210617 FILED AS OF DATE: 20210617 DATE AS OF CHANGE: 20210617 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NLS Pharmaceutics Ltd. CENTRAL INDEX KEY: 0001783036 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39957 FILM NUMBER: 211024634 BUSINESS ADDRESS: STREET 1: ALTER POSTPLATZ 2 CITY: STANS STATE: V8 ZIP: CH-6370 BUSINESS PHONE: 41-41-618-80-00 MAIL ADDRESS: STREET 1: ALTER POSTPLATZ 2 CITY: STANS STATE: V8 ZIP: CH-6370 6-K 1 ea142886-6k_nlspharmaceutics.htm REPORT OF FOREIGN PRIVATE ISSUER

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of June 2021

 

Commission file number: 001-39957

 

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

 

Alter Postplatz 2

CH-6370 Stans, Switzerland

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____

 

 

 

 

CONTENTS

 

On June 17, 2021, the Registrant convened an Ordinary Shareholders’ Meeting, or the Meeting. At the Meeting, a quorum was present, and the shareholders of the Registrant approved all agenda items as originally proposed.

 

1

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  NLS Pharmaceutics Ltd.
     
Date: June 17, 2021 By: /s/ Alexander Zwyer
    Name:  Alexander Zwyer
    Title: Chief Executive Officer

 

 

2